In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age19-70
SponsorGreen Cross Wellbeing

About this trial

Control group : LAENNEC subcutaneous injection (4 ml)

Experimental group : LAENNEC intravenous injection (10 ml)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

At the time of screening, 19 or 70 years

Those who have been diagnosed with alcoholic or non-alcoholic fatty liver disease

Those who have increased ALT level (Increased ALT level : 60 IU/L ≤ ALT ≤ 200 IU/L)

A person who can complete the signature agreement and comply with clinical trial requirements.

Disqualifiers

If you have the following disease

Liver cancer or other malignant tumor within 5 years at screening point

Esophageal varix bleeding, hepatic coma, ascites etc. related disease or Child-Pugh Score Class B,C patient within 1 year at screening point

Organs or bone marrow transplant experience

Trial design

Design model

Parallel

Treatments tested in this trial

  • LAENNEC (Human Placenta Hydrolysate) IV

    Drug

    Intravenous Injection

  • LAENNEC (Human Placenta Hydrolysate) SC

    Drug

    Subcutaneous Injection

Treatment groups

226 Participants
are divided into 2 treatment groups
Group A: LAENNEC 10 ml(Intravenous Injection)Experimental treatment 1 intervention
Group B: LAENNEC 4 ml(Subcutaneous Injection)Active comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in ALT level relative to baseline at 6 weeks

In order to compare the test groups and control groups, check the ALT change after 6 weeks compared to the baseline. For the 6 week ALT change amount, a civic analysis (ANCOVA) is performed with the ALT level of the base line and the tamed dynasty (alcohol liver disease/non -alcohol liver liver disease) in a covenant. In addition, depending on the normal distribution of the data, the Paired t-test or Wilcoxon's rank test is performed to confirm the difference in the average change in the military.

Time frame
week 6

Secondary outcomes

1

Change in ALT level relative to baseline at 2, 4 weeks

In order to compare the test groups and control groups, check the ALT change after 2,4 weeks compared to the baseline. For the 2,4 weeks ALT change amount, a civic analysis (ANCOVA) is performed with the ALT level of the base line and the tamed dynasty (alcohol liver disease/non -alcohol liver liver disease) in a covenant. In addition, depending on the normal distribution of the data, the Paired t-test or Wilcoxon's rank test is performed to confirm the difference in the average change in the military.

Time frame
week 2, 4
2

Change in AST, Total Bilirubin and r-GT level relative to baseline at 2, 4, 6 weeks

In order to compare the test groups and control groups, check the AST, Total Bilirubin and r-GT change after 2,4,6 weeks compared to the baseline. For the 2, 4, 6 weeks AST, Total Bilirubin and r-GT change amount, a civic analysis (ANCOVA) is performed with the ALT level of the base line and the tamed dynasty (alcohol liver disease/non -alcohol liver liver disease) in a covenant. In addition, depending on the normal distribution of the data, the Paired t-test or Wilcoxon's rank test is performed to confirm the difference in the average change in the military.

Time frame
week 2, 4, 6
3

The rate of ALT normalization at 2, 4, 6 weeks

Check the difference by conducting Chi-Square Test or Fisher's Exact Test for the number and ratio of the ALT normal level at 2, 4, 6 weeks.

Time frame
week 2, 4, 6
4

The rate of AST normalization at 2, 4, 6 weeks

Check the difference by conducting Chi-Square Test or Fisher's Exact Test for the number and ratio of the AST normal level at 2, 4, 6 weeks.

Time frame
week 2, 4, 6

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.